Measles is one of the most highly infectious diseases of humans and was responsible for 134 200 deaths worldwide in 2015 [1] . Infection with measles has an immunosuppressive effect extending 2-3 years beyond the initial infection and therefore vaccination and prevention of disease has beneficial effects beyond simply reducing the number of measles cases [2] . Although the global number of deaths has decreased 79% since 2000 [1] , the global campaign to eradicate measles has been impeded by an increase in the number of measles cases between 2011 and 2014, with a large proportion of these cases occurring in China [3, 4] . An original goal to eliminate measles by 2012 within China was not met [5] , in part because a large proportion of measles case patients are infants aged <8 months who are too young to be vaccinated [4, 6] . Between 2005 and 2014, 24 .04% of all measles cases in Tianjin (n = 2997) were in infants aged <1 year [6] .
Both active and passive immunity play important roles in protecting individuals and populations against measles. Active immunity is achieved through immunization with live measles vaccine or through natural infections. Passive immunity can be induced artificially (ie, through administration of immunobiologics like immune globulin) or naturally when maternal antibodies are transferred transplacentally from mother to fetus during the last trimester of pregnancy [7] . With full-term gestation and adequate nutrition, the mother will actively transport measles antibodies across the placenta such that the infant's titer at birth is higher than the mother's titer [8] . One study in Urumqi, China, found that 91.2% of young infants had protective levels of measles antibodies, compared with only 84.8% of their mothers [9] . Because maternal antibodies in infants have a half-life of 25-48 days [8] , measles antibody titers can quickly drop below protective levels.
The amount of antibody transferred from mother to child varies based on several factors. Mothers with a history of natural infection have higher antibody titers than mothers who have been vaccinated [10] [11] [12] [13] . For example, among 214 pregnant women in Belgium, 74% of vaccinated women versus 92% of women naturally infected with measles had protective levels of measles antibodies [14] . In recent years, it has increasingly become more common for children to be born to mothers who have been vaccinated versus those who have acquired immunity through natural infection. Many women are also giving birth at older ages than in the past, and this increase in initial childbearing age may be associated with decreased antibodies in the mother and subsequently decreased antibodies transfered to the infant [12] . As measles becomes less common in the population, mothers will become less exposed to subclinical "boosting" from exposure to naturally circulating disease [12] .
Immunizing infants at an age when the titer of maternally derived antibodies becomes too low to confer protection is a primary strategy for preventing measles. Because the degree of transplacental transfer, maternal antibody titers, and rate of decay in infants vary by country and by region, universal guidelines for the age at vaccination are probably not practical; rather, it is recommended that timing of vaccination be decided based on the regional context, vaccination history, disease incidence, vaccination coverage, presence of antibodies in children, and the likelihood of protective response to vaccination [12] . In general, the World Health Organization (WHO) has recommended the first dose of measles vaccine to be given at 9 months, but many developed countries, such as the United States, have extended this to 12 months because of the reduced chance for interference from circulating maternal antibodies and higher effectiveness of the vaccine at this age [15, 16] . In China, the first dose of a measles-containing vaccine is given at 8 months and has been widely available since 1978 [17] . A second dose of measles-containing vaccine was recommended in 1986 at age 7 years, but this was changed to age 18-24 months in 2005 [17] . Tianjin, along with some other regions of China, offers a third dose at age 5 years.
Characterizing the relationship between maternal and infant antibodies can inform the development of a recommended schedule for measles vaccination while also assisting China with meeting its measles control goals [4, 18] . We undertook a study to examine the relationship of measles antibody titers in mother-infant dyads in Tianjin, China. This study quantifies the age-specific decreases in maternal antibodies to measles in infants and examines the impact of maternal and infant characteristics on infant antibody titers.
METHODS
Tianjin is a provincial-level municipality with a population of 15.6 million in 2016. It is one of the largest urban population centers in China, and its Centers for Disease Control and Prevention (CDC), which houses the municipality's surveillance systems and notifiable disease control programs, reports directly to the national China CDC. The municipality includes urban, suburban, and rural districts. It also has a large proportion of nonlocals, or migrants who have recently moved to the city, often from more rural areas in the western part of the country. In 2016, 33.1% of the population were nonlocals.
Study Population
Mother-infant dyads were enrolled into a measles case-control and seroprevalence study in Tianjin from 2011 to 2015 [19] . Unvaccinated infants aged <8 months, along with their mothers, are included in the analysis. These mother-infant dyads were selected through a 2-stage sampling design. In the first stage, we selected 120 rural villages or urban communities. Villages/communities were selected using a population proportionate to size procedure, with the added stipulation that there was at least 1 village/community from each of the 16 districts in Tianjin. Within the village/community, infants were identified through local immunization clinics. Approximately equal numbers of infants from 3 age categories (<3 months, 3-5 months, and 6-8 months) were enrolled into the study. Infants aged <1 month were not enrolled into the study because their records had not yet been entered into the immunization clinics. Enrollment numbers varied because some selected villages did not have enough infants in each of the identified age stratum. The sample size was calculated based on a desired age-stratified confidence interval of <14%, which corresponded to a research aim in the larger seroprevalence study [20] .
For every participant, 4-5 bloodspots containing approximately 100 µL of serum each were collected by a finger or heel prick (depending on age of participant) with a sterile lancet. Questionnaires were administered in person by trained interviewers, and the dried bloodspot specimen cards were delivered to the Tianjin CDC where the dried bloodspots were tested for measles immunoglobulin G (IgG) antibodies as an indicator of immune protection against measles [21] . Measles IgG testing was conducted using SERION ELISA classic measles IgG (quantitative) (Institut Virion/Serion GmbH, Würzberg, Germany). According to a study from Australia, the use of dried bloodspots to test for measles antibodies is 90.2% sensitive and 98.8% specific, compared with a serum standard [22] . Threshold levels for IgG antibody test results were defined as >200 IU/mL for positive, 150-200 IU/mL for borderline, and <150 IU/mL for negative, using standards from the Standardization Administration of the People's Republic of China [23] and in accordance with previous research [24] .
Multiple Imputation of Antibody Titer Values
The antibody testing kit had a limit of detection of 50 IU/mL. We classified any values under this number as missing and imputed 100 values using IVEware version 0.2 (Survey Research Center, University of Michigan, Ann Arbor). We predicted the antibody values (whose imputed values were bounded between 0 and 50) with the following variables: mother's age, residency status, urbanicity, sex, and mother's history of immunity. Because the distributions of mothers' and infants' antibody titers were not normally distributed, we used a log base 10 transformation before imputing values.
Statistical Analysis
To examine the relationship between maternal characteristics and infant antibody levels, we conducted several statistical tests. The change in maternal antibodies was modeled in a linear regression with a natural log-transformed outcome. The model included a quadratic term for time (in 1-mo increments). To account for differences in intercept and slope values by maternal antibody levels, we grouped mothers into 4 categories based on their antibody titers (≥800 IU/mL, 400 to <800 IU/mL, 200 to <400 IU/mL, and <200 IU/mL) and specified an interaction term between the time variables and these 4 categories. This regression model describes how antibody titers decreased in older aged infants and explains variation in this decline by the mothers' antibody titers. Subsequently, the distribution of demographic and immunity characteristics was compared across antibody categories with a Pearson's χ 2 test.
We separately modeled the relationship between infant or maternal characteristics and infant antibodies. This regression model provides predictions of infant antibody titers using infant characteristics as explanatory variables. Maternal antibody levels were not included in this model because they would mediate the relationship between the mother's history of measles immunity and infant antibody titers. The precision of estimates was evaluated with 95% confidence intervals (CIs). All analyses were performed in SAS version 9.3 (SAS Institute, Cary, NC). Data management was performed using the OpenClinica database system version 3.3 (OpenClinica LLC, Waltham, MA).
Sensitivity Analysis
As a sensitivity analysis for the regression models, which relied on a multiple imputation, we compared results from the multiple imputation to an alternate approach. In the alternate approach, a negative binomial regression model was specified. Details about this analysis and the results are found in Supplementary  Tables 1 and 2 . Results from the negative binomial regression model were comparable with the findings in this article.
Ethical Review
Prior to enrollment in the study, as part of the informed consent process, a detailed explanation of study objectives, interview process, and blood sampling procedure were provided to all potential participants. Written informed consent was obtained for participation in the study for both mothers and their infants. This study was approved by both the University of Michigan Health Sciences and Behavioral Sciences Institutional Review Board and the Ethics Committee of the Tianjin CDC.
RESULTS
A total of 605 infants aged ≤8 months and their mothers were enrolled in the study; 54 infants were excluded because they had been vaccinated for measles. Among the remaining 551 mother-infant dyads, 259 (47.0%) infants and 5 (0.9%) mothers had antibody levels <50 IU/mL. Because this was the limit of detection of the enzyme kit, their values had to be imputed. Slightly more than half of the infants were male (54.5%) and living in urban areas (53.7%). Most children (90.2%) had local residency (Table 1 ). Figure 1 shows the mean, median, and distribution of antibody titers by infants' age.
Children whose mothers had an antibody titer ≥800 IU/ mL had a mean antibody titer of 542.5 IU/mL at 1 month of age (95% CI, 421.3-698.5), which was higher than children whose mother had an antibody titer of 400 to <800 (mean, 202.2; 95% CI, 148.2-275.9), 200 to <400 (mean, 113.2; 95% CI, 84.4-151.9), or <200 (mean, 48.0; 95% CI, 33.8-68.1). Figure 2 graphically depicts the differences among children by maternal antibody titer level. We observed progressively lower antibody titers in older infants. After 3 months of age, the average antibody titer in all infants was <200 IU/mL, the threshold for immune protection, regardless of mother's antibody titer.
To describe differences between mothers with different levels of antibody titers, mothers were split into 4 categories based on their antibody titers: (1) <200 IU/mL (ie, unprotected), (2) 200 to <400 IU/mL, (3) 400 to <800 IU/mL, and (4) ≥800 IU/mL (Table 2) . Mothers in the lowest antibody titer group were more likely to be nonlocals (15%) than mothers whose antibody titers were ≥800 (7%; P = .04). Urbanicity also varied across these 4 groups of mothers' antibody titers: among the 128 women whose antibody titers were 200 to <400 IU/mL, only 9% were from suburban areas, whereas 24% of women whose antibody titers were ≥800 IU/mL lived in suburban areas (P = .004). Mothers' antibody titers did not differ by age (P = .07) or by history of measles immunity (P = .80). Across all antibody titer groups, more than two thirds of the women had an unknown source of measles immunity; they were unaware of whether they had been vaccinated or had disease in the past. In the multivariable log-linear regression (Table 3) , the intercept was 156.64 (95% CI, 116.88-209.93), which was the antibody titer for children at 1 month of age with reference characteristics (male, urban, local, and whose mothers were 30 years of age with no history of measles disease or vaccination). Nonlocal infants had 1.37 times higher antibody titers than local infants (95% CI, 1.03-1.83). Compared with mothers with no known history of disease or vaccination, mothers who had a known history of measles disease had 1.60 times higher titers (95% CI, 1.06-2.43), but mothers with a history of vaccination or an unknown immunity history had comparable antibody titers. Infant's sex and urbanicity and mother's age did not significantly contribute to explaining variance in the outcome.
DISCUSSION
In this study of measles antibody titers in mother-infant dyads in Tianjin, China, we found extremely low levels of protection against measles in neonates overall and progressively lower levels of protective maternal antibodies across increasing infant age groups. At 3 months of age, almost all infants lack a protective titer of maternal antibodies, regardless of the antibody titer in their mothers. These findings are important because Tianjin has struggled with measles control in the context of China's larger elimination efforts, despite near universal immunization coverage among young children [25, 26] and the completion of 2 major supplementary immunization activities in the past 10 years, which have each targeted hundreds of thousands of children for vaccination [27] . With administration of the initial measles dose at 8 months of age, China's immunization program attempts to strike a balance between immunizing at earlier ages to provide protection to these infants, who form an increasing proportion of all case patients, and the poorer immune response elicited at earlier ages [15] .
Other recent research in China has also found low levels of antibody protection in young infants. Among infants aged <8 months, only 16.67% in Hubei province and 35.80% in Shanghai were protected against measles [28, 29] , and 37.5% of children aged <12 months (by which time some would have been vaccinated) were susceptible in Jiangxi province [30] . One study from Guangzhou province examined seropositivity by infant's age in months. Less than half of infants aged 5-7 months were measles seropositive, compared with 84.1% of infants aged 0-1 months [31] . The reasons behind low levels of measles protection in Chinese infants is difficult to investigate, given that most mothers cannot recall either their measles disease or measles vaccination history. The mothers in our study were born between 1970 and 1996. Therefore, the oldest mothers in our study were born shortly after the introduction of the measles vaccine into the Chinese market in 1966 [32] , although the vaccine was not widely disseminated and available until 1978 [17] . A second dose of measles vaccine was first recommended in 1986 [17] , although at that time children were vaccinated with the second dose when they were 7 years of age, meaning that relatively few mothers in our study would have received 2 doses of measles vaccine when they were children. Between 1983, the year when the WHO started collecting immunization data from China, and 1996, reported coverage of measles vaccine dose 1 varied between 63% and 98%, with coverage <95% for 9 of the 14 years [33] . Consequently, the mothers in our study were born at a time when measles incidence and the corresponding likelihood of exposure and acquisition of natural infection were decreasing. Moreover, mothers may not have been vaccinated, and even if vaccinated, would have a potentially lower than expected rate of seroconversion given that only 1 dose of measles vaccine was received: vaccine effectiveness for infants aged 9-11 months is estimated to be 84.0% (interquartile range, 72.0%-95.0%) [15] .
The United States has also experienced a trend wherein women born shortly after the start of the measles program have relatively low measles antibody levels. The US program on measles immunization began in 1963 [7] , approximately 15 years (26) 41 (32) 39 (22) 25-27 y 25 (25) 23 (16) 31 (24) 52 (29) 28-30 y 25 (25) 48 (34) 33 (26) 40 (22) 31-42 y 28 (27) 35 (24) 23 (18) (24) 25 (17) 12 (9) 34 (19) Rural 21 (21) 37 (26) 54 (42) 48 (27) Mother's education .18
≤Middle school 35 (34) 38 (27) 55 (43) 67 (38) High school 14 (14) 15 (10) 12 (9) 20 (11) Vocational education 24 (24) 39 (27) 34 (27) 39 (22) College 29 (28) 51 (36) 27 (21) 52 (29) Mother's history of measles immunity .80
Disease 4 (4) 7 (5) 7 (5) 15 (8) Vaccination and not disease 13 (13) 13 (9) 15 (12) 14 (8) Unknown 70 (69) 102 (71) 86 (67) 125 (70) Neither disease nor vaccination 15 (15) 21 (15) 20 (16) 24 (13) a Pearson's χ 2 test of independence [34] .
Policy and Program Implications
Age at vaccination is an important determinant of vaccine efficacy because of potential interference from maternal antibodies and due to maturation of the infant's immune system [35] . Studies in China have shown lower seroconversion at younger ages. For example, in Hubei province, 81% of vaccinees were antibody positive at 6 months of age, 91% were at 7 months of age, and 94% were at 8 months of age [36] . The proportion of the study population converting after a single vaccination was slightly lower in Guangxi province, where 70% of children aged 6-10 months, 97% of children aged 11-12 months, and 90% of children aged 13-23 months seroconverted [37] . One strategy to mitigate morbidity in young infants would be to vaccinate children as young as 6 months, or even 4.5 months, while recognizing lower vaccine efficacy at this age. Because China has a successful routine immunization system, these children would likely be quickly revaccinated at an older age when the vaccine is more effective. More research is needed about whether earlier vaccination is cost-effective, taking into consideration the need to educate providers and parents about this additional shot at a time when many Chinese parents express concern about the number of vaccines that young infants aged <6 months receive [38] . Another approach to increase vaccine titers in young infants would be to vaccinate women of childbearing age before pregnancy [39, 40] and ensure they receive 2 doses of vaccine, although the effectiveness of this approach across China has not been investigated nor does China currently have widespread adult vaccination programs. Identifying mothers with low antibody titers and vaccinating their children at an early age has been proposed, but this strategy is probably not cost-effective [41] . Lastly, identifying common locations of transmission, such as hospitals [42] , and instituting stricter infection control measures could also limit the spread of disease to susceptible infants.
Strengths and Limitations
This study had several limitations. This was a cross-sectional study, so we did not observe the decay of antibodies within a single infant over time. Additionally, because we did not enroll children at birth, we did not measure antibody levels in the neonate, which could help us better understand the efficiency of antibody transfer. Our study was limited in its ability to draw conclusions about how maternal history of measles disease or measles vaccination impacts transfer of antibodies and decay of these antibodies because most mothers could not recall having disease or the vaccine, and instead we pursued analyses using direct measures of antibody titers. Nevertheless, by sampling infants and mothers throughout Tianjin, we were able to construct a study relatively free of selection biases. Additionally, we have rigorously analyzed the degradation of maternal antibodies among infants in 2 regression models that have separately (1) evaluated how antibody titers in the infant are impacted by the titers in the mother, but this discrepancy is washed out after a few months, after which infants are largely unprotected, and (2) modeled how antibody titers in the infant are a function of the infant's age and residency status (with nonlocals having a higher titer), but not other demographic variables like sex, urbanicity, or mother's age.
Conclusions
We found most infants in this Tianjin-based study were susceptible to measles. In our model of antibody decay, even among infants born to mothers with high titers of measles antibodies, we found that the overwhelming majority were susceptible to measles by 4 months of age. Because most mothers have an unknown vaccination and disease history status, developing targeted programs for high-risk mothers is probably not feasible. Vaccinating the entire cohort of mothers who were born as the Chinese measles vaccination program was ramping up, and who therefore may either have only received 1 measles vaccine dose or have an unknown vaccination history, is one possible strategy to reduce transmission to infants. However, China currently does not have widespread adult vaccination programs. Another strategy would be instituting vaccination programs for infants aged <6 months, while also recognizing that the immune response is suboptimal at younger ages. Immunizing infants at this earlier age would likely represent an additional dose beyond the current 2-dose schedule. The addition of another measles vaccination to the schedule would add costs to the program, although these costs ostensibly would be offset by reductions in ongoing transmission in infants and greater prevention of serious illness and measles-related mortality in this highly vulnerable age group.
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